When.com Web Search

Search results

1. Results From The WOW.Com Content Network

2. Cancer team 'allowed me to dream I had a future' - AOL

   www.aol.com/news/cancer-team-allowed-dream-had...

   Olwen Kramer underwent six different types of treatment in seven years, including a stem cell transplant, after being diagnosed with non-Hodgkin lymphoma - a type of blood cancer - 24-years ago ...

3. Non-Hodgkin lymphoma - Wikipedia

   en.wikipedia.org/wiki/Non-Hodgkin_lymphoma

   Non-Hodgkin lymphoma (NHL), also known as non-Hodgkin's lymphoma, is a group of blood cancers that includes all types of lymphomas except Hodgkin lymphomas. [1] Symptoms include enlarged lymph nodes, fever, night sweats, weight loss, and tiredness. [1] Other symptoms may include bone pain, chest pain, or itchiness. [1]

4. Rituximab - Wikipedia

   en.wikipedia.org/wiki/Rituximab

   Rituximab, sold under the brand name Rituxan among others, is a monoclonal antibody medication used to treat certain autoimmune diseases and types of cancer. [18] It is used for non-Hodgkin lymphoma, chronic lymphocytic leukemia (in children and adults, but not recommended in elderly patients), rheumatoid arthritis, granulomatosis with polyangiitis, idiopathic thrombocytopenic purpura ...

5. Indolent lymphoma - Wikipedia

   en.wikipedia.org/wiki/Indolent_lymphoma

   Indolent lymphoma, also known as low-grade lymphoma, is a group of slow-growing non-Hodgkin lymphomas (NHLs). [3] Because they spread slowly, they tend to have fewer signs and symptoms when first diagnosed and may not require immediate treatment. Symptoms can include swollen but painless lymph nodes, unexplained fever, and unintended weight ...

6. T cell/histiocyte-rich large B-cell lymphoma - Wikipedia

   en.wikipedia.org/wiki/T_cell/histiocyte-rich...

   The addition of immunotherapy drug, rituximab, to the CHOP regimen appears to have improved these results: in one study, patients receiving the R-CHOP regimen had a three-year overall survival rate of 75%. [8] Since treatment of the variant form of nodular lymphocyte predominant Hodgkin lymphoma using different and less aggressive drug regimens ...

7. Targeted Alpha Therapy Clinical Trials Overview

   lite.aol.com/tech/story/0022/20250129/9349458.htm

   Beyond solid tumors, hematological malignancies such as chronic lymphocytic leukemia (CLL) and non-Hodgkin’s lymphoma are also under consideration for TAT treatment. Research on anti-CD37-targeted therapies, including 212Pb-NNV003, has yielded encouraging preclinical findings, demonstrating substantial anti-proliferative effects on cancer ...